UNSPSC 51281675: Streptomycin sulfate

This classification denotes an aminoglycoside antibiotic with the molecular formula 2C21H39N7O12.3H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CW25IKJ202, chemically known as streptomycin, sulfate (2:3) (salt) but more generally known as streptomycin sulfate, which bears US NIH Compound Identifier 19648. European Medicines Agency schedules Streptomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04593MIG.

Most nations, for tariff and trade purposes, schedule streptomycin sulfate under HS 29412080 and SITC 54132. Streptomycin sulfate bears US NLM identifiers UMLS ID C0038426 and NCI Concept Code C47729. SMILES: As of Q4 2014, STREPTOMYCIN SULFATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51281675 Streptomycin sulfate is a Commodity code that nominally describes a single antibiotic product, but the recent state and local opportunities tagged under it show little alignment with that scope—instead, the procurement activity under this code encompasses a broader range of pharmaceutical and medical supply purchases, including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and first-aid supplies. State and local issuing bodies using this code include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances. The work being solicited is primarily supply procurement and vendor contracting for pharmaceuticals, over-the-counter products, and emergency medical supplies distributed to public health facilities, fire rescue operations, and state employee health plans.

Recent activity spans multiple states and issuing-body types. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline; Seminole County, Florida issued an IFB on June 30, 2026 for naloxone and drug deactivation systems with a July 26, 2023 deadline; the City of Tampa's Purchasing Department posted an IFB on March 25, 2026 for medical and first aid supplies (estimated contract value $700,000) with a March 13, 2026 deadline and SLBE set-aside eligibility; and the Texas Health and Human Services Commission issued an RFI on April 3, 2026 exploring direct-to-manufacturer prescription fulfillment models. The code shows activity in Florida, Texas, and Minnesota, with cooperative purchasing vehicles (MMCAP) representing multi-state participation. However, the mismatch between the code's nominal pharmaceutical substance and the actual procurement scope suggests either coding inconsistency in source systems or use of this code as a catch-all for medical and pharmaceutical procurement rather than specific streptomycin sulfate purchases.